Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Other Non-Current Liabilities (2020 - 2025)

Sonoma Pharmaceuticals has reported Other Non-Current Liabilities over the past 9 years, most recently at $5.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 8.52% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $5.5 million, up 8.52%, while the annual FY2025 figure was $5.1 million, 9.17% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $5.5 million at Sonoma Pharmaceuticals, up from $5.4 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $5.5 million in Q4 2025 and troughed at $3.5 million in Q1 2021.
  • A 5-year average of $4.4 million and a median of $4.4 million in 2023 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: rose 12.85% in 2021 and later grew 8.52% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $3.8 million in 2021, then increased by 9.22% to $4.1 million in 2022, then rose by 12.06% to $4.6 million in 2023, then increased by 9.69% to $5.0 million in 2024, then increased by 8.52% to $5.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SNOA at $5.5 million in Q4 2025, $5.4 million in Q3 2025, and $5.2 million in Q2 2025.